Treatment

Loncastuximab Tesirine and Epcoritamab clinical trials

1 indexed studies · 1 currently recruiting

Not yet recruitingPHASE2
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
This study looks at a new combination of two medicines, Loncastuximab Tesirine and Epcoritamab, for people in the UK with aggressive B-cell lymphoma that has come back or hasn't responded to previous treatments. It's for adults aged 18 and over.
For: Aggressive Diffuse Large B-cell Lymphoma · High-grade B-cell Lymphoma (HGBL) · Follicular Lymphoma (FL) Grade 3B
Germany